Merck Boosts 2026 Sales Forecast – What Investors Should Watch

Merck lifts its 2026 sales outlook to $65 billion, topping analyst consensus by 8%.

Merck's 2026 Sales Forecast Surge

■Sales target: $65 billion (up from $60 billion prior estimate)

■Annual growth rate: 8%

■Key driver: Strong demand in oncology and vaccine segments

■CEO: Robert M. Pettit's strategic guidance

Oncology: The Engine of Growth

Merck's oncology portfolio, anchored by Keytruda and the emerging Libtayo combo, posted 12% YoY growth. The segment now accounts for 35% of total revenue.

Profit Margins and Cash Flow Outlook

■Gross margin: 75%

■Free cash flow: $9 billion

■Projected EPS: $9.5

■Dividend yield: 3.2%

Investor Valuation Lens

Following the upgraded outlook, the market trims Merck's P/E to 18x, while EV/EBITDA settles at 10x. This suggests a 7% upside potential for the stock.

Strategic Share Buyback & Dividend Policy

■Buyback program: $10 billion (2024‑2026)

■Dividend increase: 5% annual uplift plan

■Goal: 40% return on equity

Expert Note (Aylin Güneş): Merck's sales lift is underpinned by durable growth in oncology and vaccines. The robust buyback and dividend strategy enhances the risk‑reward profile for long‑term value investors. The stock trades at a modest discount to its revised outlook, presenting an attractive entry point for dividend‑and‑buyback‑focused portfolios.